Atlas creates second opportunity fund with $300M; BioNTech's colorectal cancer vaccine starts PhII trial
Life science VC Atlas Venture closed its second Opportunity Fund with $300 million. Known as AVOF II, the fund will enable Atlas to continue backing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.